GPCR as reported
- Net Income
- −$215M
Net Income · +20% year on year · trailing twelve months to Q2 2026
- Free Cash Flow
- −$225M
Free Cash Flow · +37% year on year · trailing twelve months to Q2 2026
- EPS
- −$1.01
EPS · −3.8% year on year · trailing twelve months to Q2 2026
| Series | Latest | Year on year | As of |
|---|---|---|---|
| Net Income | −$215M | +20% | Q2 2026 |
| EPS | −$1.01 | −3.8% | Q2 2026 |
| ROE | −16% | n/a | Q2 2026 |
| ROA | −15% | n/a | Q2 2026 |
| Free Cash Flow | −$225M | +37% | Q2 2026 |
Every figure straight from the statements as filed with the SEC, no scoring, no adjustment. Open a series for its full history.
Structure Therapeutics Inc. (GPCR) - Net IncomeNet IncomeStructure Therapeutics Inc. (GPCR)